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Trends in Endocrinology & MetabolismReviewImpacts of Caffeine during Pregnancy
Jingjing Qian,1 Qi Chen,2 Sean M. Ward,3 Enkui Duan,1,* and Ying Zhang1,4,*Highlights
A growing, robust body of evi-
dence from both epidemiological
and animal studies unveils harmful
effects of maternal gestational
caffeine exposure, even from doses
previously considered ‘safe.’
Rodent studies revealed that
caffeine exposure during specific
stages of pregnancy may disrupt
embryo transport, embryo devel-
opment, embryo implantation, and
placental function, leading to
pregnancy complications.
Notably, caffeine sensitivity is
highly variable from individual to
individual. Genetic variations and
epigenetic regulation, intermin-
gling with intrinsic and environ-
mental factors, might play pivotal
roles in shaping the complex
phenotypic variability. Exploring
the underlyingmechanism(s) will be
helpful, not only for improving the
guidelines of gestational caffeine
consumption, but also for person-
alized dosing of drugs that interact
with caffeine at the pharmacoki-
netic or pharmacodynamic level.
Evidence from rodent studies
demonstrated that in utero caffeine
exposure triggered car-
diometabolic defects on both the
immediate offspring and subse-
quent generations. Further studies
are needed regarding caffeine’s
long-term effects and multigener-Epidemiological studies have revealed that caffeine consumption during pregnancy is associated
with adverse gestational outcomes, yet the underlying mechanisms remain obscure. Recent an-
imal studies with physiologically relevant dosages have begun to dissect adverse effects of
caffeine during pregnancy with respect to oviduct contractility, embryo development, uterine
receptivity, and placentation that jointly contribute to pregnancy complications. Interestingly,
caffeine’s effects are highly variable between individual animals under well-controlled experi-
mental settings, suggesting the possibility of epigenetic regulation of these phenotypes, in addi-
tion to genetic variants. Moreover, caffeine exposure during sensitive windows of pregnancy
may induce epigenetic changes in the developing fetus or even the germ cells to cause adult-
onset diseases in subsequent generations. We discuss these research frontiers in light of
emerging data.
A Snapshot of Caffeine’s Impacts
Caffeine is the most widely consumed psychoactive substance throughout the world [1,2]. In the USA,
approximately 70% of women continue to consume caffeine during pregnancy [3,4]. It has been re-
ported that some women consume more than 300–500 mg of caffeine per day during pregnancy
[5], which is the equivalent of approximately three to five 240 ml cups of coffee daily (https://www.
fda.gov). Although caffeine consumption in adults has beneficial effects on neurological diseases
(e.g., Parkinson’s and Alzheimer’s diseases), cardiovascular diseases (e.g., coronary heart disease,
stroke), certain cancers (e.g., prostate cancer, melanoma, liver cancer, breast cancer), liver diseases
(e.g., liver fibrosis, liver cirrhosis) and type 2 diabetes [6,7], it has also been well documented that
maternal caffeine consumption during pregnancy increases the risk of pregnancy failure or gesta-
tional complications [6,7], the underlying mechanisms of which are just beginning to be revealed.
Importantly, the effects of caffeine exposure on reproductive performance vary greatly from individ-
ual to individual [5,8–10], which could be a result of combined effects of genetic variants, epigenetic
factors, and environmental inputs that jointly predispose individual sensitivity. The study of caffeine’s
heterogeneous effects within a well-controlled animal cohort may provide an ideal model in which to
study the genetic and epigenetic bases of phenotypic variation (see Glossary) that may account for
the different individual sensitivity towards caffeine and thus may lead to future solutions in precision
medicine. In addition, recent studies have begun to provide evidence showing that caffeine exposure
during pregnancy can cause adverse effects to the offspring, or even subsequent generations [11],
suggesting possible epigenetic regulation through early embryonic or fetal germ cells via the
maternal environment; this has triggered great interest and warrants further in-depth mechanistic
study. Here, in light of recent research findings, we discuss these emerging topics of gestational
exposure to caffeine, especially focusing on animal and human studies with physiologically relevant
dosages that may shed light on the impacts, of daily caffeine consumption.1State Key Laboratory of Stem Cell and
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ational influence in humans.Caffeine’s Negative Impacts on Pregnancy: Evidence from Humans
Caffeine’s effects on gestational health have received widespread attention since the 1980s [12]. Dur-
ing pregnancy, caffeine’s metabolic rate in mothers is significantly decreased, especially after the first
trimester [13], and the half-life of caffeine increases from 2.5–4.5 hours to approximately 15 hours to-
wards the end of pregnancy [2]. Moreover, caffeine is lipophilic enough to freely transfer across all
biological membranes, including the blood–placental barrier, while neither fetus nor placenta has
the enzymes for its metabolism [14]; caffeine absorbed by mothers may also accumulate in oviductal
or uterine fluid environments [15], which potentially affects embryonic development and generates
adult-onset diseases. Epidemiological studies showed that caffeine consumption during pregnancy
was associated with intrauterine growth retardation (IUGR)/low birth weight [12], subfertility [16],
and spontaneous abortion [17] (Figure 1A). A ‘safe’ maximum caffeine dosage for gestational healthTrends in Endocrinology & Metabolism,--, Vol.--, No.-- https://doi.org/10.1016/j.tem.2019.11.004
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Figure 1. Maternal Caffeine Intake Compromises Pregnancy and Birth Outcomes.
(A) In humans, caffeine intake during pregnancy may give rise to pregnancy complications, such as miscarriage
[4,17], fetal growth restriction [5,12], and low birth weight [21–24], which would also increase the risk of
overweight and impaired cognitive development in childhood [25–27]. (B) Potential mechanisms for the effects
of caffeine as revealed by a rodent model. Current studies show that maternal caffeine exposure not only
severely disrupts embryo implantation but also disrupts ongoing midterm fetal growth and development,
resulting in pregnancy loss, low birth weight, and impaired brain development in offspring on postnatal day 6
(P6) [35–38,55]. Abbreviations: GABA, g-aminobutyric acid; IUGR, intrauterine growth retardation.
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Trends in Endocrinology & Metabolismhas been previously claimed: daily intake of less than 300 mg caffeine (approximately three cups of
coffee) during pregnancy was deemed unlikely to harm gestational health [10,18]. However, this
‘safe’ dosage is being reevaluated based on increasing evidence, which has shown that even daily
doses of less than 300 mg may increase the risk of pregnancy failure [17,19–21]. Furthermore, other
studies found that even a daily intake as low as 100–200 mg during pregnancy is associated with
an increased risk of miscarriage [4], fetal growth restriction [5], low birth weight [22–24], as well as
increased risks to the offspring, including cognitive development impairments [25], overweight,
and obesity [26,27]. These studies raise concern that there may be no one absolute ‘safe’ threshold
of caffeine consumption during pregnancy [5,21,22,27,28].
Despite the differences in gestation and fetal development, caffeine absorption and bioavailability
are generally similar between humans and rodents [29], which has allowed for the opportunity to
understand caffeine’s physiological and molecular effects through the use of animal models. Ac-
cording to human studies, nearly 99% of caffeine is absorbed across the wall of the gastrointestinal
(GI) tract within approximately 30–45 minutes [1,2], and the pharmacokinetics of caffeine are inde-
pendent of the route of administration, since there is a negligible first-pass effect for caffeine
metabolism [2,29]. Caffeine is primarily metabolized in the liver by the cytochrome-450 oxidase
enzyme system in which CYP1A2 (cytochrome P450 1A2) is the rate-limiting enzyme that is respon-
sible for the clearance of the absorbed caffeine (95% in humans [29] and 87% in mice [30]) and is
the main isoform detected in the livers of both humans and rodents [31]. Under physiological con-
ditions, caffeine generates its cellular effects by blocking adenosine receptors, mainly through
ADORA1 (adenosine A1 receptor) and ADORA2A (adenosine A2A receptor) [2,32], which are
conserved across species between humans and rodents [33]. Therefore, rodent studies in well-
controlled experimental settings may provide insights into the cellular mechanisms underlying caf-
feine’s effects on human pregnancy.2 Trends in Endocrinology & Metabolism,--, Vol.--, No.--
Glossary
Adenosine receptors: a family of
G protein-coupled receptors,
comprising subtypes A1, A2A, A2B,
and A3, with adenosine as an
endogenous ligand; common
nonselective antagonists of these
receptors include caffeine and
theophylline.
Blood–placental barrier: a struc-
ture composed of layers of cells
that prevents diffusion of sub-
stances between the mother and
fetus; this barrier changes over the
course of pregnancy.
Embryo implantation: a stage of
pregnancy at which the activated
blastocyst adheres to the recep-
tive uterus.
First-pass effect: also known as
first-pass metabolism; an orally
administered substance absorbed
from the GI tract first enters the
liver through the portal vein, and a
proportion of it, to what extent
depends on the specific sub-
stance, must be metabolized in
the GI tract or liver before reaches
the systemic circulation.
Genital ridge: also known as
gonadal ridge; a mesodermal
primordium of the somatic go-
nads in the vertebrate embryo.
Hypothalamic-pituitary-adrenal
axis: a complex neuroendocrine
system composed of the hypo-
thalamus, pituitary gland, and
adrenal gland, acting through
direct effects or feedback in-
teractions among these compo-
nents to control neuroendocrine
functions, such as stress response
and immunoregulation.
Implantation window: a limited
stage in which the uterus is
conducive to the activated blas-
tocyst to initiate implantation,
which is principally regulated by
ovarian steroids estrogen and
progesterone.
Intrauterine growth retardation
(IUGR): a condition in which the
fetus is abnormally small while in
the mother’s womb, causing
pregnancy complications,
including low birth weight, still-
birth, and long-term develop-
mental defects.
Isthmus of the fallopian tube: the
narrow part of the fallopian tube
that links the ampulla (beginning
of the fallopian tube near the
ovary) to the uterotubal junction
(connection between the fallopian
tube and the uterus).
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Trends in Endocrinology & MetabolismPathophysiological Impacts of Caffeine on Pregnancy: Insights from Rodent
Studies
Consistent with the results from human epidemiological studies, caffeine exposure in rodents causes
similar adverse effects on pregnancy outcomes and fetal development (Figure 1B). In the following
discussion, caffeine dosages used in rodents are extrapolated to the equivalents of 240 ml cups of
coffee consumption in humans, which is based on equal circulating levels of caffeine after consump-
tion by rodents or humans [2,11,34–36]. Mice exposed to high dosages of caffeine, equivalent to
about six or 12 cups of coffee in humans, 1 week prior to and during the entire period of gestation,
resulted in delayed conception, decreasedmaternal bodyweight gain and placenta weight, as well as
increased risks of IUGR, fetus resorption, and low birth weight [37]. Importantly, recent studies have
further revealed that brief caffeine exposure during early pregnancy or even the preconception
period can induce a ripple of adverse effects throughout the whole pregnancy. Female rats adminis-
trated with a dosage, equivalent to six cups of coffee in humans, for 4 consecutive days before
conception had reduced fertility due to impaired embryo implantation [38]. Disrupted embryo im-
plantation was also found when mice were treated with a dosage equivalent to nine cups of coffee
or one to two cups of coffee per day in humans during preimplantation [35] (Figure 1B). These obser-
vations are closely related to human health and raise a red flag for caffeine consumption before em-
bryo implantation and prior to any signs of pregnancy that can be clinically recognized. Moreover, a
series of studies also demonstrated that maternal diet during this period can also affect long-term
health of offspring [39]. Therefore, for women who are planning to conceive, restricted caffeine con-
sumption should be considered for future clinical guidance.
Mechanistically, caffeine-induced implantation failure could be partially ascribed to delayed
oviductal embryo transport, as preimplantation caffeine exposure can result in embryo retention in
the isthmus of the fallopian tube [35]; this in vivo observation is consistent with previous ex vivo
data showing that caffeine abolished the generation of electrical slow wave pacemaker activity and
the underlying rhythmic contractility of the oviduct smooth muscle via a cAMP-dependent pathway
[40]. Impaired oviductal embryo transport is detrimental to the ongoing fetal development, as it
has been previously established that a brief delay in transport would cause the embryo to miss the
implantation window and generate adverse ripple effects in future embryonic development [41].
Caffeine treatment during the preimplantation stage also disrupted early embryo development
and compromised blastocyst quality, potentially through a direct effect on the developing embryo,
as demonstrated by in vitro caffeine treatment, or through an in vivo secondary effect involving
disruption of the oviductal/uterine environment, or both. In addition, dysregulation of steroid hor-
mone-regulated genes, such as leukemia inhibitory factor (Lif), mucin 1 (Muc1), lactoferrin (Ltf), and
amphiregulin (Areg), which are important determinants of uterine receptivity, was also found in pre-
implantation uterine epithelium after caffeine treatment, suggesting impaired uterine receptivity
(Figure 1B). All of these factors may act together to cause abnormal embryo implantation and thus
lead to further pregnancy complications and pregnancy loss [35].
In addition to early gestational exposure, caffeine exposure during the middle and late stages of preg-
nancy also leads to a variety of adverse effects. For example, a single administration of caffeine, with a
dosage equivalent to two cups of coffee in humans, in pregnant mice on embryonic day 8.5 can impair
embryonic cardiac development and reduce ventricular myocardial area as well as cardiac output and
contractility, resulting in compromised cardiac function in adulthood [34,42]. When caffeine was admin-
istered daily to pregnant mice during days 9.5 to 18.5, with a modest dosage equivalent to one cup of
coffee in humans, it was capable of disrupting embryonic cardiovascular growth and function [36] (Fig-
ure 1B). Using the adenosine A2A receptor antagonist [36] and an adenosine A1 receptor knockout
mouse model [42], it was demonstrated that the effects of caffeine on cardiac function are mediated
by blockade of adenosine receptor signaling [36,42]. Moreover, the effects of caffeine on embryo devel-
opment could also be a result of impaired placental function, as demonstrated by decreased placental
weight and abnormal structure after caffeine treatment during mid-to-late pregnancy in rats, which
could be acting through chronic activation of maternal and placental renin–angiotensin system and in-
duction of tumor protein p53-dependent trophoblast apoptosis [37]. In addition, a single administrationTrends in Endocrinology & Metabolism,--, Vol.--, No.-- 3
(A)
(B)
Interindividual variability in caﬀeine response
Regulatory network of caﬀeine eﬃcacy
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Figure 2. Interindividual Variability in Caffeine Response.
Postulated models underpinning the highly variable individual response to caffeine exposure. (A) Women showed
different responses to caffeine exposure during pregnancy [5,8,9,45,46]. (B) The effects of caffeine might be
regulated by multiple factors in vivo, including the ability to metabolize caffeine (determined by the rate-
limiting enzyme CYP1A2) and cellular targets (mainly through ADORA1/A2A), or regulated through modulators
associated with pregnancy and fetal development, all of which modify the outcome of pregnancy for individual
women after caffeine exposure. Abbreviations: ADORA1, adenosine A1 receptor; ADORA2A, adenosine A2A
receptor; CYP1A2, cytochrome P450 1A2.
Phenotypic variation: the differ-
ences in a given phenotype be-
tween individuals in a population,
considered a prerequisite for
adaptation and evolution.
Precision medicine: a developing
approach to disease prevention
and treatment that is tailored to
variations in an individual’s genes,
environment, and lifestyle, aiming
to improve therapeutic efficacy
and safety while alleviating
adverse side effects.
Primordial germ cells (PGCs):
gamete precursors that develop
into haploid germ cells, that is,
sperm and eggs, which generate a
new organism upon fertilization.
Spontaneous abortion: also
termed miscarriage; induced em-
bryonic or fetal death before the
20th week of pregnancy, when the
embryo or fetus cannot survive
independently.
Uteroplacental circulation: the
connection between the uterus
and placenta, which plays a
pivotal role in nutrient, oxygen,
and waste exchange between the
mother and the fetus.
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Trends in Endocrinology & Metabolismof caffeine on day 12 of pregnancy in rats significantly reduced blood flow to the maternal ovary, uterus,
and decidua [43], which may lead to vasoconstriction in the uteroplacental circulation and compromise
the ability of the placenta to transfer nutrients to the developing embryo. Moreover, increased serum
adrenaline concentration and significantly decreased (25%) intervillous placental blood flow have
been reported in pregnant women after ingesting two cups of coffee during the last trimester [44].
These findings suggest that middle and late gestational caffeine exposure can have a profound effect
on both embryonic and placental development, and could explain the observed IUGR associated with
gestational caffeine consumption in humans [5].
Interindividual Variation in Caffeine Response
Notably, caffeine’s effects on pregnancy outcomes have been shown to be highly variable between
individuals in both rodents [35,38] and humans [5,8,9,45,46] (Figure 2A). Substantial interindividual
phenotypic variation and the underling mechanism(s) in complex traits and diseases have become
an area of significant scientific interest over the past two decades. It is now increasingly accepted
that an individual’s disease susceptibility is a complex readout of combined effects from genetic,
epigenetic, and environmental inputs as well as their dynamic interaction during the process of devel-
opment [47,48]. However, the relative weights of these different factors in the contribution of interin-
dividual variation and disease predisposition varies case by case and depends on specific conditions
and sometimes may show significant synergism.
The individual variation in caffeine response involves its metabolism as well as the sensitivity of
adenosine receptors [29] (Figure 2B). In particular, regulation of CYP1A2, the rate-limiting enzyme4 Trends in Endocrinology & Metabolism,--, Vol.--, No.--
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Trends in Endocrinology & Metabolismin caffeine metabolism, represents a well-studied example (Figure 2B and Box 1). Epidemiological
studies have found that when exposed to the same dosages of caffeine, women with higher
CYP1A2 enzyme activity (rapid caffeine metabolism) have an increased risk of pregnancy disorders
compared to those with lower CYP1A2 enzyme activity [5,8,9,45,46]. Human CYP1A2 mRNA levels
represent more than 40-fold interindividual differences, and the in vivo activity of the CYP1A2 enzyme
varies up to 60-fold, as probed by the 3-demethylation of caffeine [49]. In addition to the constitutive
expression of hepatic CYP1A2, the activity of CYP1A2 can be regulated by a range of extrinsic and
intrinsic factors, such as induced by cigarette smoking and heavy coffee consumption, inhibited by
oral contraceptives [50], and coregulated by other liver-enriched transcription factors [51]. The regu-
lation of CYP1A2 via environmental factors may also involve multiple layers of epigenetic mechanisms
in addition to genetic variations (Box 1), which represents an exciting area for future research andmay
lead to personalized precision medicine.Prenatal Caffeine Exposure: Significance to the Long-Term Health of the
Offspring
In addition to the adverse effects on gestational outcomes, caffeine consumption during pregnancy
also affects the long-term development of the fetus and elicits adult diseases, thus reflecting the the-
ory of developmental origins of health and disease (DOHaD) [52] (Box 2). In humans, it has been found
that exposure to high dosages of prenatal caffeine significantly increases the risk of childhood acute
lymphoblastic leukemia [53]. If mothers ingested more than 200 mg of caffeine per day, their children
showed a twofold higher risk of impaired cognitive development and low IQ (intelligence quotient) at
age 5.5 years, compared with those whosemothers ingested less than 100 mg of caffeine per day [25].
Two additional independent studies both found that even low dosages (<150 mg daily) of maternal
caffeine consumption during pregnancy was associated with increased risks of offspring’s excess
growth in babyhood and overweight in early childhood [26,27]. This rapid ‘catch-up’ weight gain after
low birth weight is a prime risk factor for subsequent developmental risks of adult cardiovascular or
metabolic diseases [54]. Fetal development impairments and adult diseases caused by prenatal
caffeine exposure were similarly found in mice, showing that maternal caffeine exposure from preg-
nancy until lactation could result in possible long-term neuronal and behavior impairments in
offspring [55] (Figure 3).
Mechanistically, the adverse effects of caffeine on F1 offspring could be due to early embryo caffeine
exposure via oviductal or uterine fluid [15], or during later exposure that bypasses the blood–placenta
barrier. In addition to the direct effect of caffeine exposure, recent studies also found that caffeine
intake during mid-to-late pregnancy can cause an increase in maternal glucocorticoids [56]; fetus
exposed to such an environment can result in long-term programming of fetal hypothalamic-pitui-
tary-adrenal axis [57], which could disrupt neuroendocrine metabolism and increase susceptibility
to metabolism syndrome, such as hypercholesterolemia, in adult offspring [56,58] (Figure 3).
Beyond the F1 offspring, disorders induced by maternal caffeine exposure may also be transferred to
the second and/or third generations. Prenatal caffeine exposure in rats during mid-to-late pregnancy
can increase susceptibility to metabolic syndrome in the F2 generation [59]. Interestingly, different
cardiac phenotypes were developed in the succeeding generations, depending on the timing of in
utero caffeine exposure: pregnant mice treated with caffeine once daily, equivalent to two cups of
coffee in humans, during days 6.5–9.5 can induce dilated cardiomyopathy only in the F1 generation,
but treatment during days 10.5–13.5 caused hypertrophic cardiomyopathy in the F2 generation and
morphological changes in the F3 generation [11,60] (Figure 3). It is well known that during days 7.5–
13.5, mouse primordial germ cells (PGCs) undergo a genome-wide epigenetic reset as they migrate
and settle at genital ridges. Recent studies have found that environmental stimuli during this period,
such as dietary treatment, affect PGCs development in the fetuses and induce specific epigenetic al-
terations in germ cells, such as disrupted DNA methylation [61]. Notably, caffeine exposure during
days 6.5–10.5 can change the expression of DNAmethyltransferases Dnmt1/3a/3b [11,62], and deme-
thylases Tet1/2/3 in embryonic heart [62], which are critical in regulating DNAmethylation landscape.
Caffeine treatment during these important periods of early embryo and/or germ line developmentTrends in Endocrinology & Metabolism,--, Vol.--, No.-- 5
Box 1. Genetic and Epigenetic Regulation of CYP1A2
Two genetic variants in the CYP1A2 gene have been reported to cause different levels of CYP1A2 expression
after exposure to smoking or coffee: the variant –163C>A (rs762551) in intron 1 of the CYP1A2 gene was asso-
ciated with higher inducibility in Caucasian or Swedish smokers [71,72] and heavy coffee consumers in Serbia
and Sweden [73], while the 5’-flanking variant –3860G>A (rs2069514) conferred a decreased CYP1A2 induc-
ibility in Japanese smokers [74]. It is interesting to note that ten single-nucleotide polymorphisms in the genes
of ARNT (aryl hydrocarbon receptor nuclear translocator), AhRR (aryl hydrocarbon receptor regulator), HNF1a
(hepatocyte nuclear factor 1a), IL-1b (interleukin-1 b), SRC-1 (steroid receptor coactivator 1), and VDR (vitamin
D receptor) were suggested to be correlated with variability in CYP1A2 enzyme activity, but none of them was
located in the CYP1A locus [51], suggesting that genetic factors outside the CYP1A locus may play an impor-
tant role in establishing the genotype–phenotype relationship of CYP1A2 (Figure I). However, genetic and
environmental factors combined can explain only 30%–40% of the individual variability in CYP1A2 activity
[75,76], suggesting the complexity of CYP1A2 regulation, which may involve a layer of epigenetic regulation.
Human hepatic CYP1A2 expression was found to display allele-specific expression [77], and it was found that
environmental stimuli can directly affect CYP1A2 expression through epigenetic factors. Cigarette smoke
condensate treatment in vitro could increase the levels of H3K4me3 and H4K16ac and decrease the level of
H3K27me3 in the segments of CYP1A2 gene [78], and influence caffeine metabolism. CYP1A2 mRNA tran-
scripts were also regulated by DNA methylation. For example, the DNA methylation extent of a CpG island
(containing 17 CpG sites) close to its translation start site [77] and the CCGG site (bp-2579) in the 5’-flanking
region showed an inverse association with CYP1A2 mRNA expression [79]. Moreover, small RNAs, such as hsa-
miR-132-5p, were also found to directly target the 3’-untranslated regions of CYP1A2 mRNA and suppress the
expression of CYP1A2 protein [80]. In addition to DNA methylation, histone modifications and small RNAs
mediated epigenetic regulation of CYP1A2 expression, recent studies from monozygotic twins revealed that
the causes of phenotypic discordance also contain gene–environment interaction(s), as well as other intangible
stochastic factors [81] or epigenetic switch for bistable downstream gene expression, as shown in other sys-
tems [82] (Figure I).
(A) (B)GeneƟc variants EpigeneƟc regulaƟon
Trends in Endocrinology & Metabolism
Figure I. Genetic Variation and Epigenetic Factors may Contribute to CYP1A2-Mediated Interindividual
Variability in Caffeine Response.
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Trends in Endocrinology & Metabolismmay also affect the epigenetic state that goes beyond one generation. Importantly, fetal PGCs regain
DNAmethylation in a sex-specific manner: male germ cells reestablish methylation after day 13.5 pre-
natally, whereas female germ cells undergo remethylation after birth [61,63]. These differences may
lead to a sex-different response in offspring, which has been found in prenatal caffeine exposure
induced metabolic phenotype in rat [59]. Moreover, a considerable fraction of genomic sequences
have been found to bypass the removal of DNAmethylation during PGC and preimplantation reprog-
ramming [64], which also might contribute to caffeine exposure induced DOHaD. Besides, other
epigenetic carriers, such as histone modifications, noncoding RNAs, and RNA modifications
[65–67], may also be involved in caffeine-induced long-lasting effects across generations, as well as
the gender-dependent outcomes, which deserve more in-depth examinations in the future.6 Trends in Endocrinology & Metabolism,--, Vol.--, No.--
Box 2. Developmental Origins of Health and Disease (DOHaD)
Although scientists investigating the Dutch HungerWinter (1944–1945) in 1976 reported that in utero and early
infantile famine exposure are linked to the offspring’s obesity risk [83], David Barker greatly expanded the
concept of DOHaD from 1986 onwards, by finding high correlation between maternal starvation and increased
risk of low birth weight as well as offspring cardiometabolic diseases in adulthood [84]. This concept was sub-
sequently supported by additional reports from epidemiological and clinical studies, which found that early-
life environmental exposure, such as maternal nutrition status and mental health during the conception or early
infancy period, was strongly linked to future chronic diseases, especially noncommunicable diseases, including
obesity, certain cancers, abnormal bone density, schizophrenia, atopic dermatitis, and asthma [52,85].
Although the mechanisms underlying DOHaD are still unclear, it is well accepted that epigenetic regulation
is involved in embryonic and placental developmental disorders caused by the maternal environment pertur-
bation [52,85]. For example, individuals periconceptionally exposed to famine during the Dutch HungerWinter
were associated with altered IGF2 (insulin-like growth factor II) DMR (differentially methylated region) methyl-
ation 6 decades later [86], reinforcing the great importance of early-life experience on lifelong health condi-
tioning [39].
Outstanding Questions
What mechanisms underlie the
interindividual variation in caffeine
responses? In what ways can future
studies reveal the precise functions
or interaction of genetic variations,
epigenetic regulation, and the
environment in this complex pro-
cess? Are there any key molecules
that control an individual’s
response to caffeine?
How can one assess the personal-
ized safe dosage of gestational
caffeine intake? Is it possible to
predict the potential effects of
caffeine before pregnancy? If so,
what is the best way to formulate a
standard and personalized guide-
line for women who are preparing
to conceive?
What are the long-term conse-
quences, especially adult-onset
disease, of in utero caffeine expo-
sure in humans? Can future longi-
tudinal studies corroborate and
extend initial findings on the asso-
ciations between caffeine exposure
and certain chronic diseases in the
clinic? Questions as to whether
these adverse exposures and ef-
fects of caffeine can be transferred
into subsequent generations need
to be addressed.
To what extent, if at all, does
caffeine affect the metabolism and
efficacy of clinical drugs? Can a
person’s response to caffeine
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The World Health Organization and European Food Safety Authority recommend that daily caffeine
consumption remain below 200–300 mg as a safe dosage for pregnant health [68,69]. It is prudent to
note that the current recommended maximal dose may be too high for certain individuals. At the mo-
lecular level, the mechanisms of caffeine-induced disease susceptibility and heritability remain un-
clear, but represent an interesting model that may help us to reevaluate the effects of environmental
exposure.
Studies have provided both epidemiological and experimental evidence suggesting that the further
investigation of themechanisms involved in responsiveness to caffeinemight provide a new avenue in
precision medicine. That said, developing a rapid and efficient method to evaluate individual suscep-
tibility to caffeinewill not only be beneficial for women in pregnancy healthmanagement, but also pro-
vide a basis in the guidelines of personalized drug usage and drug discovery [70]. For example, the key
enzyme for caffeine metabolism, CYP1A2, could be pursued as a specific drug target and could be
used as the basis of personalized caffeine sensitivity tests in daily life. Finally, by what mechanism
and to what extent caffeine’s effect before or during pregnancy can affect offspring’s phenotype
are currently intriguing questions that warrant in-depth investigations (see Outstanding Questions).Trends in Endocrinology & Metabolism
Figure 3. In Utero Caffeine Exposure Triggers Adult-Onset Diseases and Transmits Adverse Effects into
Subsequent Generations.
Caffeine can freely cross the blood–placenta barrier and thus exposes the fetus. Exposure to caffeine during
pregnancy can induce long-term health disorders in subsequent generations [11,55,59]. Compromised maternal
caffeine metabolism, disrupted placenta development, and an abnormal uterine environment may affect fetal
development as well as the offspring’s health (F1), which may also influence the primordial germ cells (PGCs) of
the developing fetus and transfer diseases, such as cardiomyopathy, to the F2 descendants. Abbreviations:
IUGR, intrauterine growth retardation; HPA axis, hypothalamic-pituitary-adrenal axis.
reflect his/her potential responses
to some drugs or treatments, al-
lowing a preliminary prediction in
the clinic?
What is the best way to balance the
advantages and disadvantages of
caffeine in pregnant women, espe-
cially for those who are suffering
from neurological diseases, liver
diseases, cardiovascular diseases,
or certain cancers?
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